Polycythaemia Vera Treatment: Medicines, Diet & Management

How is Polycythaemia Vera Diagnosed?

A haematologist usually confirms polycythaemia vera using blood counts, JAK2 mutation testing and other investigations. Testing may include haemoglobin and haematocrit measurements, serum erythropoietin levels, physical examination and medical history. A bone marrow biopsy may be needed to confirm the diagnosis or to distinguish PV from other blood disorders. Doctors also assess for secondary causes of increased red blood cells before finalising treatment.

How is Polycythaemia Vera Treated Based on Severity?

Polycythaemia vera is not usually treated according to mild, moderate or severe stages. Instead, treatment is primarily guided by the risk of thrombosis and additional clinical problems such as troublesome symptoms, splenomegaly, frequent phlebotomy requirements or poorly controlled blood counts.

Treatment becomes more intensive when the risk of complications increases. The table below summarises the main risk-based treatment approaches for polycythaemia vera:

Clinical Group	Typical Treatment Approach
Lower thrombosis risk	Phlebotomy to keep haematocrit below 45% and low-dose aspirin when appropriate.
Higher thrombosis risk	Phlebotomy and aspirin plus cytoreductive treatment, commonly hydroxyurea or an interferon-based medicine.
Selected low-risk disease needing better control	Cytoreduction may be considered when symptoms are troublesome, phlebotomy is poorly tolerated or frequently required, or blood counts remain difficult to control.
Hydroxyurea-resistant or intolerant disease	Another cytoreductive option, such as ruxolitinib or an interferon-based treatment, may be considered according to the clinical situation.

The commonly used thrombosis-risk model considers previous thrombosis and age over 60 years, although treatment decisions also take individual cardiovascular and disease-related factors into account.

Stages of Polycythaemia Vera and Their Treatment

Polycythaemia vera can remain in a chronic phase for many years, but a small proportion of cases progress to more advanced blood disorders. Treatment changes substantially in this case.

The table below summarises the main phases of polycythaemia vera and their treatment direction:

Disease Phase	Treatment Direction
Chronic or proliferative PV	Phlebotomy, low-dose aspirin and cytoreductive treatment when indicated.
Post-PV myelofibrosis	Treatment is directed at myelofibrosis and may include JAK-inhibitor therapy, treatment for anaemia or other symptoms, transfusion support and, in selected people, stem cell transplantation.
Accelerated or blast-phase disease	Urgent specialist treatment is required. Therapy may include acute leukaemia-directed treatment and consideration of stem cell transplantation in eligible individuals.

Other Treatments for Polycythaemia Vera

Other treatments for polycythaemia vera that may be recommended by doctors are listed below:

Therapeutic Phlebotomy Phlebotomy removes a measured amount of blood to reduce the red cell volume. Sessions are repeated as needed to keep the haematocrit below 45%. The frequency usually decreases once blood counts are under better control.
Interferon-Based Cytoreductive Therapy Pegylated interferon or ropeginterferon alfa-2b may be used to reduce excessive blood cell production. Interferon-based treatment can be particularly useful when long-term cytoreduction is required and may also be considered in selected younger people.
Treatment of Blood Clots If thrombosis occurs, the clot requires condition-specific treatment. Anticoagulation or other treatment may be needed depending on whether the clot is venous or arterial and on the person's bleeding risk.
Treatment During Pregnancy Pregnancy requires specialist monitoring because polycythaemia vera can increase the risk of blood clots and pregnancy-related complications. Treatment approach by doctors may include careful haematocrit control, low-dose aspirin when appropriate and interferon-based cytoreductive therapy. Some other cytoreductive medicines are generally avoided during pregnancy.
Stem Cell Transplantation Stem cell transplantation is not used for uncomplicated chronic polycythaemic vera. It may be considered in selected people if the disease progresses to higher-risk post-PV myelofibrosis or acute leukaemia.

Oral Medications for Polycythaemia Vera

Oral medicines for polycythaemic vera are selected according to thrombosis risk, symptoms and the need for cytoreduction. Common oral medications for polycythaemia vera treatment that may be prescribed by doctors are given below:

Low-dose Aspirin: Helps reduce clotting risk when there is no important contraindication.
Hydroxyurea: Reduces blood cell production and is commonly used when cytoreductive treatment is required.
Ruxolitinib: May be used when hydroxyurea is ineffective or not tolerated and can also improve splenomegaly and disease-related symptoms.
Anticoagulants: May be prescribed after certain blood clots according to the type of thrombosis and bleeding risk.
Antihistamines: May provide limited relief from itching in some people.

Ayurvedic and Alternative Treatments for Polycythaemia Vera

There is no established ayurvedic, herbal or alternative treatment that can control the abnormal blood cell production in polycythaemia vera. Yoga, gentle stretching, meditation and relaxation exercises may support general well-being and stress management.

Herbal products should not replace phlebotomy, aspirin or prescribed cytoreductive treatment and should be discussed with the treating doctor, as some products may affect bleeding or interact with medicines.

Home Care for Managing Polycythaemia Vera

Home care can support prescribed treatment and help reduce avoidable complications. Some home care measures for polycythaemia vera that may be useful are given below:

Stay adequately hydrated unless fluid intake has been medically restricted.
Take prescribed medicines consistently and attend scheduled blood tests and phlebotomy sessions.
Avoid smoking and prolonged periods of inactivity.
Use cool or lukewarm water, moisturisers or cool compresses if water-related itching is troublesome.
Seek urgent care for chest pain, sudden breathlessness, severe headache, weakness, speech difficulty or unusual swelling in a limb.

How Long Does Polycythaemia Vera Treatment Take?

Polycythaemia vera is a chronic condition, so monitoring generally continues throughout life. Individual treatments may be adjusted, stopped or changed according to blood counts, complications and response.

Treatment duration differs according to the therapy used. The table below summarises approximate durations for various treatments of polycythaemic vera:

Treatment	Approximate Duration
Therapeutic phlebotomy	Repeated as needed; frequency usually falls once haematocrit is controlled.
Low-dose aspirin	Often long-term when appropriate and well tolerated.
Hydroxyurea or interferon-based treatment	Usually ongoing while effective and tolerated.
Ruxolitinib	Usually continued long-term while it remains effective and safe.
Blood-count Monitoring	Frequent during treatment changes, followed by regular long-term monitoring once stable.

Polycythaemia Vera Treatment Side Effects

Possible polycythaemia vera treatment-related side effects are given below:

Dizziness or fatigue after phlebotomy
Iron deficiency
Stomach irritation or bleeding
Low blood cell counts
Mouth ulcers or skin problems
Flu-like symptoms
Headache
Mood changes
Increased susceptibility to some infections
Injection-site reactions
Anaemia

Side effects should be reviewed by the treating doctor because changing the dose or treatment may sometimes be necessary.

Lifestyle Changes for Managing Polycythaemia Vera

Healthy habits can support the treatment of polycythaemia vera and reduce additional cardiovascular risk. Some lifestyle changes for managing polycythaemia vera are listed below:

Stay physically active within safe limits.
Maintain a healthy body weight and a balanced diet.
Avoid smoking and tobacco.
Limit excessive alcohol intake.
Manage blood pressure, cholesterol and diabetes when present.
Avoid remaining seated or immobile for long periods.
Attend regular medical and blood count reviews.

Triggers That Can Worsen Symptoms of Polycythaemia Vera

Certain factors may make symptoms more noticeable or increase the risk of complications from polycythaemia vera. These factors are given below:

Dehydration
Smoking
Prolonged inactivity
Hot baths or showers for people with water-related itching
Poorly controlled cardiovascular risk factors
Missing prescribed treatment or necessary monitoring

Treatment Cost of Polycythaemia Vera in India

The cost of polycythaemia vera treatment in India varies widely. Treatment managed mainly with medical consultations, blood tests, phlebotomy, aspirin, or hydroxyurea generally incurs lower expenses than that involving interferon, ruxolitinib, frequent specialist care or hospital treatment.

In general, the annual cost of polycythaemic vera treatment in India, including phlebotomy and medicines, could reach ₹5,00,000 or more in some cases.

Routine care may incur lower costs, while targeted medicines and advanced treatment can increase annual costs significantly. Treatment expenses also depend on the city, hospital, medicine, monitoring frequency and health insurance coverage.

Does Health Insurance Cover Treatment of Polycythaemia Vera in India?

Yes. Health insurance provides for polycythaemia vera. It pays for medically necessary hospitalisation, in-patient procedures, treatments and pre & post-hospitalisation expenses. Routine doctor consultations, outpatient phlebotomy and oral medicines may require OPD cover.

In case polycythaemic vera has been diagnosed before policy purchase, it will be considered a pre-existing illness and a waiting period of up to 3 years has to be served. Waiting periods, pre-existing condition clauses, exclusions, co-payments and sub-limits should be reviewed before treatment.

Frequently Asked Questions (FAQs)

Q1. Is there any cure for polycythaemia vera?

Ans: There is currently no standard cure for polycythaemia vera. Controlling blood counts and reducing the risk of complications are the main goals of treatment of PV. Stem cell transplantation is considered only in selected advanced cases.
Q2. What is the first-line treatment of polycythaemia vera?

Ans: Commonly used first-line treatment for polycythaemia vera usually includes phlebotomy and low-dose aspirin, as recommended by doctors. Cytoreductive treatment is added for higher-risk or selected symptomatic disease.
Q3. Why is aspirin prescribed in polycythaemia vera?

Ans: Low-dose aspirin is used in polycythaemia vera to reduce platelet activity and lower the risk of blood clots when it can be taken safely.
Q4. What is done in case of resistance/ intolerance to hydroxyurea in polycythaemia vera?

Ans: When hydroxyurea is ineffective or not tolerated in polycythaemia vera, ruxolitinib or an interferon-based treatment may be considered according to individual needs.
Q5. Is medicine always necessary for polycythaemia vera, or can phlebotomy alone suffice?

Ans: Cytoreductive medicine is not always required for polycythaemia vera. Low-risk disease is often managed with phlebotomy and low-dose aspirin when aspirin is suitable.
Q6. Can polycythaemia vera lead to something more serious?

Ans: Yes. Polycythaemia vera can occasionally progress to post-PV myelofibrosis or acute leukaemia, so long-term monitoring is important.
Q7. What is the frequency of blood count testing in the case of polycythaemia vera?

Ans: Blood counts are checked more frequently when polycythaemia vera treatment begins or changes, and less often once the condition is stable. The exact schedule is individualised.
Q8. Does polycythaemia vera need lifelong treatment?

Ans: Polycythaemia vera usually requires lifelong monitoring. Treatment may continue long-term or change over time according to blood counts, symptoms and complications.